Received Jul 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | IM |
inadvertently given menveo 1 year apart and once at 13 and once at 14 years old; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a child female patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Previously administered products included Menveo (received 1st dose at age of 13 years old). On 23-JUL-2025, the patient received the 2nd dose of Menveo (intramuscular) .5 ml. On 23-JUL-2025, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: inadvertently given menveo 1 year apart and once at 13 and once at 14 years old). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 24-JUL-2025 The reporter reported that they have inadvertently given Menveo 1 year apart which was once at 13 and once at 14 years old, which led to extra dose administered. The reporter asked was there any side effects or problems that they should know about, and she will still need another at 16 years, correct